相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Jonathan W. Goldman et al.
LANCET ONCOLOGY (2021)
Memory-like HCV-specific CD8+ T cells retain a molecular scar after cure of chronic HCV infection
Nina Hensel et al.
NATURE IMMUNOLOGY (2021)
Immunocompetent Mouse Models in the Search for Effective Immunotherapy in Glioblastoma
Roxanne Wouters et al.
CANCERS (2021)
Combination immunotherapy strategies for glioblastoma
Hok Yee Chan et al.
JOURNAL OF NEURO-ONCOLOGY (2021)
Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells
Rebekka Duhen et al.
NATURE COMMUNICATIONS (2021)
Cell-programmed nutrient partitioning in the tumour microenvironment
Bradley Reinfeld et al.
NATURE (2021)
Differentiation of exhausted CD8+ T cells after termination of chronic antigen stimulation stops short of achieving functional T cell memory
Pierre Tonnerre et al.
NATURE IMMUNOLOGY (2021)
Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40
Fan Yang et al.
NATURE COMMUNICATIONS (2021)
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages
John de Groot et al.
NEURO-ONCOLOGY (2020)
CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas
Joseph A. Flores-Toro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open -label phase III study
R. L. Ferris et al.
ANNALS OF ONCOLOGY (2020)
OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody
Hirofumi Ohmura et al.
BRITISH JOURNAL OF CANCER (2020)
ICOS Is an Indicator of T-cell-Mediated Response to Cancer Immunotherapy
Zunyu Xiao et al.
CANCER RESEARCH (2020)
Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer
Ying Ma et al.
GASTROENTEROLOGY (2020)
Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth
Tsutomu Nakazawa et al.
CELLS (2020)
PD-1: Its Discovery, Involvement in Cancer Immunotherapy, and Beyond
Yasumasa Ishida
CELLS (2020)
Translational Nanomedicine Boosts Anti-PD1 Therapy to Eradicate Orthotopic PTEN-Negative Glioblastoma
Hiroaki Kinoh et al.
ACS NANO (2020)
Local Targeting of NAD+ Salvage Pathway Alters the Immune Tumor Microenvironment and Enhances Checkpoint Immunotherapy in Glioblastoma
Ming Li et al.
CANCER RESEARCH (2020)
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
Kurt A. Schalper et al.
NATURE MEDICINE (2019)
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
Timothy F. Cloughesy et al.
NATURE MEDICINE (2019)
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
Junfei Zhao et al.
NATURE MEDICINE (2019)
Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition
Aida Karachi et al.
NEURO-ONCOLOGY (2019)
Triple combination immunotherapy with GVAX, anti-PD-1 monoclonal antibody, and agonist anti-OX40 monoclonal antibody is highly effective against murine intracranial glioma
Nusrat Jahan et al.
ONCOIMMUNOLOGY (2019)
Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment
Adela Wu et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses
Daisuke Sugiura et al.
SCIENCE (2019)
First-in-human trial of blood-brain barrier opening in amyotrophic lateral sclerosis using MR-guided focused ultrasound
Agessandro Abrahao et al.
NATURE COMMUNICATIONS (2019)
Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy
Anna Galstyan et al.
NATURE COMMUNICATIONS (2019)
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
T. A. Chan et al.
ANNALS OF ONCOLOGY (2019)
CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma
Bryan D. Choi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy
Carmela Passaro et al.
CLINICAL CANCER RESEARCH (2019)
Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody
Danbee Ha et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer
Erminia Massarelli et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells
Nusrat Jahan et al.
NEURO-ONCOLOGY (2018)
Current state of immunotherapy for glioblastoma
Michael Lim et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study
Luana Calabro et al.
LANCET RESPIRATORY MEDICINE (2018)
OX40 expression in hepatocellular carcinoma is associated with a distinct immune microenvironment, specific mutation signature, and poor prognosis
Kunlin Xie et al.
ONCOIMMUNOLOGY (2018)
Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas
Jennifer E. Kim et al.
CLINICAL CANCER RESEARCH (2017)
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
Austin G. Duffy et al.
JOURNAL OF HEPATOLOGY (2017)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment
Susanne M. Steggerda et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Understanding the Intersections between Metabolism and Cancer Biology
Matthew G. Vander Heiden et al.
CELL (2017)
Anti-GITR therapy promotes immunity against malignant glioma in a murine model
Jason Miska et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Rescuing defective tumor-infiltrating T-cell proliferation in glioblastoma patients
Song Han et al.
ONCOLOGY LETTERS (2016)
Successful Treatment of a Patient with Glioblastoma and a Germline POLE Mutation: Where Next?
Alexandra Snyder et al.
CANCER DISCOVERY (2016)
Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity
Francis Mussai et al.
CANCER RESEARCH (2015)
OX40 Ligand Contributes to Human Lupus Pathogenesis by Promoting T Follicular Helper Response
Clement Jacquemin et al.
IMMUNITY (2015)
OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy
Ichiyo Shibahara et al.
MOLECULAR CANCER (2015)
Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, 0X40, GITR, CD27, CD28, and ICOS
Miguel F. Sanmamed et al.
SEMINARS IN ONCOLOGY (2015)
Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
Derek A. Wainwright et al.
CLINICAL CANCER RESEARCH (2014)
Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment
Francis Mussai et al.
BLOOD (2013)
Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation
Linda V. Sinclair et al.
NATURE IMMUNOLOGY (2013)
Expression of Indoleamine 2,3-Dioxygenase and Correlation With Pathological Malignancy in Gliomas
Kentaro Mitsuka et al.
NEUROSURGERY (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Christiane A. Opitz et al.
NATURE (2011)
Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4
Omar S. Qureshi et al.
SCIENCE (2011)
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
S. J. O'Day et al.
ANNALS OF ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival
Jonathan R. Brody et al.
CELL CYCLE (2009)
The significance of OX40 and OX40L to T-cell biology and immune disease
Michael Croft et al.
IMMUNOLOGICAL REVIEWS (2009)
Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy Laboratory investigation
Takeshi Miyazaki et al.
JOURNAL OF NEUROSURGERY (2009)
Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4(+) T cell compartment without affecting regulatory T-cell function
Peter E. Fecci et al.
CLINICAL CANCER RESEARCH (2007)
CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction
E Contardi et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion
JX Song et al.
IMMUNITY (2005)
The costimulation-regulated duration of PKB activation controls T cell longevity
JX Song et al.
NATURE IMMUNOLOGY (2004)
Distinct robes of CTLA-4 and TGF-β in CD4+CD25+ regulatory T cell function
QZ Tang et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
C Uyttenhove et al.
NATURE MEDICINE (2003)
CD4+CD3- accessory cells costimulate primed CD4 T cells through OX40 and CD30 at sites where T cells collaborate with B cells
MY Kim et al.
IMMUNITY (2003)
Constitutive OX40/OX40 ligand interaction induces autoimmune-like diseases
K Murata et al.
JOURNAL OF IMMUNOLOGY (2002)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
The interaction properties of costimulatory molecules revisited
AV Collins et al.
IMMUNITY (2002)
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease
L Monney et al.
NATURE (2002)
PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine
T Okazaki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells
PR Rogers et al.
IMMUNITY (2001)
Tryptophan degradation by human placental indoleamine 2,3-dioxygenase regulates lymphocyte proliferation
Y Kudo et al.
JOURNAL OF PHYSIOLOGY-LONDON (2001)
ICOS is critical for T helper cell-mediated lung mucosal inflammatory responses
JA Gonzalo et al.
NATURE IMMUNOLOGY (2001)
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice
H Nishimura et al.
SCIENCE (2001)
ICOS co-stimulatory receptor is essential for T-cell activation and function
C Dong et al.
NATURE (2001)
ICOS is critical for CD40-mediated antibody class switching
AJ McAdam et al.
NATURE (2001)
ICOS is essential for effective T-helper-cell responses
A Tafuri et al.
NATURE (2001)
Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation
S Read et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
T Takahashi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
分享论文
